ONCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ONCY is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below its pivot and shows weak near-term momentum, while the available signals do not indicate a strong entry today. I would hold off on buying now and wait for clearer confirmation of strength.
Current price is 0.91585, slightly above the previous close of 0.8991, with the regular session essentially flat. Technicals are mixed to weak: MACD histogram is positive but contracting, RSI_6 at 41.582 is neutral to slightly weak, and moving averages are converging, which usually signals indecision rather than an established uptrend. Price is below the pivot level of 0.941 and only modestly above support at 0.884, so the stock is trading in a narrow range without strong breakout confirmation. The candlestick-pattern trend model also suggests downside bias over the next day, week, and month.
The biggest positive catalyst is the scheduled Type C meeting with the FDA on April 16 to align on the design of a single-arm pivotal study for pelareorep in squamous cell anal carcinoma. Lake Street also maintained a Buy rating despite lowering the price target, which shows the company still has some support from the sell side. Pre-market and post-market moves were positive, suggesting some speculative interest after the latest update.
No news in the past week means there is no fresh momentum catalyst. Hedge funds and insiders are both neutral, so there is no visible accumulation signal. The analyst price target was cut from $7 to $5, which is still above the current price but indicates reduced confidence. The pattern-based trend model points to negative returns over the near term. No congress trading data or notable politician buying/selling was reported.
Latest quarter financials were not provided clearly due to an error in the financial snapshot, so a full quarter-over-quarter assessment is not available. Based on the context, the key financial focus remains on clinical and regulatory progress rather than revenue growth. For a beginner long-term investor, the lack of usable quarterly financial detail makes it harder to justify an immediate buy.
Lake Street analyst Chad Messer lowered the price target to $5 from $7 on 2026-04-07 while keeping a Buy rating after FY25 results and ahead of the FDA Type C meeting. This is a mixed Wall Street view: still bullish on the story, but with a meaningfully lower target that reflects more caution. Overall, pros still see upside if the FDA meeting goes well, but the lowered target and lack of recent news suggest the conviction is not strong enough to call this a clear buy today.
